Almuth F. Kessler

Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.

TERT Promoter Mutations and Risk of Recurrence in Meningioma.

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma.

Feasibility of the Combined Application of Navigated Probabilistic Fiber Tracking and Navigated Ultrasonography in Brain Tumor Surgery.

Screening for symptom burden and supportive needs of patients with glioblastoma and brain metastases and their caregivers in relation to their use of specialized palliative care.

CXCR4: A new player in vestibular schwannoma pathogenesis.

O-(2-(F)fluoroethyl)-L-tyrosine PET for the differentiation of tumour recurrence from late pseudoprogression in glioblastoma.

Prognostic Value of O-(2-[F]Fluoroethyl)-L-Tyrosine PET/CT in Newly Diagnosed WHO 2016 Grade II and III Glioma.

Identification of KIF11 As a Novel Target in Meningioma.

Circulating MACC1 Transcripts in Glioblastoma Patients Predict Prognosis and Treatment Response.

Cytotoxic T Cells and their Activation Status are Independent Prognostic Markers in Meningiomas.

[Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas.

Clinical Utility of Different Approaches for Detection of Late Pseudoprogression in Glioblastoma With O-(2-[18F]Fluoroethyl)-L-Tyrosine PET.

ADAM9: A novel player in vestibular schwannoma pathogenesis.

Glioma patients in outpatient care-optimization of psychosocial care in neuro-oncological patients (GLIOPT): Protocol for a cluster randomized controlled trial.

The Emesis Trial: Depressive Glioma Patients Are More Affected by Chemotherapy-Induced Nausea and Vomiting.

Tumor Treating Fields (TTFields) Induce Cell Junction Alterations in a Human 3D In Vitro Model of the Blood-Brain Barrier.

Characterization and Optimization of the Tumor Microenvironment in Patient-Derived Organotypic Slices and Organoid Models of Glioblastoma.